Search for Clinical Trial Results
Myelofibrosis - 57 Studies Found
Status | Study |
Active, not recruiting |
Study Name: Study to Compare Busulfan-fludarabine With Thiotepa-fludarabine Regimen in Allogeneic Transplantation for Myelofibrosis Condition: Myelofibrosis Date: 2013-03-14 Interventions:
|
Completed |
Study Name: Pilot Trial of Arsenic + Cytarabine in Patients With Myelofibrosis Condition: Myelofibrosis Date: 2007-12-11 Interventions:
|
Recruiting |
Study Name: A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis Condition: Myelofibrosis Date: 2017-02-27 Interventions:
|
Completed |
Study Name: Allogeneic Stem Cell Transplantation (SCT) After Dose-reduced Conditioning for Myelofibrosis Patients Condition: Myelofibrosis Date: 2008-01-11 Interventions: Procedure: Allogeneic Stem Cell Transplantation Allogeneic Stem Cell Transplantation after dose-reduced |
Recruiting |
Study Name: Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg Condition: Myelofibrosis Date: 2016-03-08 Interventions:
|
Active, not recruiting |
Study Name: Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis Condition: Myelofibrosis Date: 2012-12-24 Interventions: Drug: Peginterferon alfa-2a 50 mcg subcutaneous injection once per week |
Suspended |
Study Name: Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor Condition: Primary Myelofibrosis Date: 2015-04-21 Interventions:
|
Terminated |
Study Name: A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial) Condition: Primary Myelofibrosis Date: 2014-03-06 Interventions: Drug: Ruxolitinib Starting dose was based on reason for previous discontinuation of ruxolitinib (i.e. lo |
Completed |
Study Name: Thalidomide in Treating Patients With Myelofibrosis Condition: Primary Myelofibrosis Date: 2001-05-06 Interventions:
|
Withdrawn |
Study Name: A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis Condition: Primary Myelofibrosis Date: 2015-10-21 Interventions: Biological: Pacritinib QD (Once a day) |